ProArc Medical

ProArc Medical, an Israeli-based medical device company founded in 2010, is focused on developing minimally invasive treatments for benign prostatic hyperplasia (BPH). The company was founded by Dr. Yair Feld, a serial entrepreneur with a background in medicine, holding both M.D. and Ph.D. degrees from the Technion-Israel Institute of Technology and currently practicing at Rambam Medical Center. The leadership team includes CEO Gilad Hizkiyahu, who has over 20 years of experience in engineering and management, particularly in multidisciplinary medical devices, and holds a BSc in Aerospace Engineering and an MBA. The company operates in the urology market, specifically targeting the prevalent issue of BPH, which affects a significant portion of the aging male population worldwide.

ProArc Medical's flagship product is the Omega procedure, previously known as the ClearRing System, a device designed to alleviate lower urinary tract symptoms (LUTS) caused by an enlarged prostate. This system utilizes a C-shaped, super-elastic nitinol implant that is embedded into the prostate tissue, creating a supportive structure that reshapes the prostatic urethra to allow for improved urine flow. The procedure is minimally invasive and can be completed in approximately three minutes under reduced anesthesia. The implant is delivered via a specialized device that performs a small circular incision for placement, avoiding long-term contact with urine and mitigating risks like encrustation. A key benefit is the preservation of sexual function, a common complication associated with more invasive surgical treatments like transurethral resection of the prostate (TURP). Furthermore, the procedure is reversible, as the implant can be retrieved if necessary.

The business model centers on the sale of this medical device to healthcare providers, such as urologists and hospitals. ProArc Medical has conducted clinical trials to validate the safety and efficacy of its technology, demonstrating improvement in urological function without significant side effects. The company has secured intellectual property protection with granted patents in the U.S. and Europe. Funding has been acquired through multiple rounds, including grants from the European Union, and investments from firms like The Trendlines Group, positioning the company for potential market launch and commercialization.

Keywords: ProArc Medical, benign prostatic hyperplasia, BPH treatment, LUTS, Omega procedure, ClearRing System, minimally invasive urology, medical device, nitinol implant, prostate reshaping, urology, men's health, Yair Feld, Gilad Hizkiyahu, The Trendlines Group, non-surgical BPH treatment, urethral implant, reversible BPH procedure, sexual function preservation, medical technology